EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study

Raluca Lupusoru iD, Lavinia Cristina Moleriu, Ruxandra Mare, Ioan Sporea iD, Alina Popescu, Roxana Sirli, Adrian Goldis, Camelia Nica, Tudor Voicu Moga iD, Bogdan Miutescu iD, Iulia Ratiu iD, Oana Belei und 3 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms27010201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Raluca Lupusoru und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department III, Functional Science, Discipline of Medical Informatics and Biostatistics, "Victor Babes" University of Medicine and Pharmacy, 300041 T…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania;, “Victor Babes” University of Medicine and Pharmacy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) remains difficult to manage in patients who fail multiple therapeutic lines, and growing evidence suggests that alterations in the gut microbiome contribute to persistent symptoms and inflammatory activity. This study evaluated a three-month, AI-guided, multi-omic personalized microbiome modulation program in adults with treatment-refractory IBD. Baseline stool metagenomic sequencing, blood biomarkers, micronutrient panels, and clinical data were integrated through an artificial intelligence platform to generate individualized plans combining dietary adjustments, targeted synbiotics, selective antimicrobials, and micronutrient correction. Clinical outcomes, inflammatory markers, and microbial signatures were reassessed after three months. Across 358 participants, stool frequency decreased substantially, urgency and rectal bleeding resolved in most patients, and over 70% reported a “much improved” overall condition. Inflammatory biomarkers showed marked normalization, with reductions in hs-CRP and fecal calprotectin observed in over 85% of cases. Micronutrient deficiencies, particularly iron and zinc, also improved, and beneficial microbial taxa such as Faecalibacterium prausnitzii, Bifidobacterium longum, and Akkermansia muciniphila increased significantly. These findings suggest that personalized, multi-omic microbiome modulation may support clinically meaningful improvements by targeting microbial, metabolic, and immune imbalances rather than symptoms alone. While encouraging, these results require confirmation in randomized controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesGastrointestinal MicrobiomeHumansMultiomicsFemaleMaleAdultBiomarkersFecesMiddle AgedTreatment OutcomeMicronutrientsInflammation

Stichwörter der Autor:innen

artificial intelligence–guided therapygut microbiome modulationimmunometabolisminflammatory bowel disease (IBD)microbiome–immune interactionsmulti-omicspersonalized medicineshort-chain fatty acid–producing bacteria

Substanzen

BiomarkersMicronutrients

Autor:innen und Institutionen

  • Department III, Functional Science, Discipline of Medical Informatics and Biostatistics, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Center for Modeling Biological Systems and Data Analysis, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Gastroenterology and Hepatology Clinic, County Emergency Hospital "Pius Brinzeu", 300723 Timisoara, Romania.
  • Advanced Regional Research Center in Gastroenterology and Hepatology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Department of Internal Medicine II, Division of Gastroenterology and Hepatology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • First Pediatric Clinic, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

ORCID-Profile: Raluca Lupusoru, Ioan Sporea, Tudor Voicu Moga, Bogdan Miutescu, Iulia Ratiu, Radu Dumitru Dragomir

Förderung

  • "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania;
  • “Victor Babes” University of Medicine and Pharmacy

Zitieren

APA

Lupusoru, R., Moleriu, L. C., Mare, R., Sporea, I., Popescu, A., Sirli, R., Goldis, A., Nica, C., Moga, T. V., Miutescu, B., Ratiu, I., Belei, O., Olariu, L., Dumitrascu, V., & Dragomir, R. D. (2025). AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010201

Vancouver

Lupusoru R, Moleriu LC, Mare R, Sporea I, Popescu A, Sirli R, et al. AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010201

BibTeX
@article{Lupusoru2025,
  author = {Lupusoru, Raluca and Moleriu, Lavinia Cristina and Mare, Ruxandra and Sporea, Ioan and Popescu, Alina and Sirli, Roxana and Goldis, Adrian and Nica, Camelia and Moga, Tudor Voicu and Miutescu, Bogdan and Ratiu, Iulia and Belei, Oana and Olariu, Laura and Dumitrascu, Victor and Dragomir, Radu Dumitru},
  title = {AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms27010201}
}
Kostenlos starten →